A Study of Lerociclib in Participants With Advanced Breast Cancer

  • End date
    May 15, 2026
  • participants needed
  • sponsor
    EQRx, Inc.
Updated on 15 June 2022


This is a multicenter, single-arm, open-label study to evaluate the safety and efficacy of lerociclib in combination with standard endocrine therapy in female or male participants with HR+/HER2- MBC. The study population will consist of either newly diagnosed, treatment naïve participants with HR+/HER2- MBC (1L population) and participants with HR+/HER2- MBC who have already progressed on first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin for at least 28 days prior to entering the study and will remain on goserelin throughout the study, in accordance with the prescribing information and according to the study site's standard practice.

Condition Advanced Breast Cancer
Treatment Lerociclib + Letrozole or Fulvestrant
Clinical Study IdentifierNCT05085002
SponsorEQRx, Inc.
Last Modified on15 June 2022


Yes No Not Sure

Inclusion Criteria

Participant must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent
Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer
Advanced (locoregionally recurrent not amenable to curative therapy, eg, surgery and/or radiotherapy, or metastatic) breast cancer
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1
Adequate bone marrow and organ function
Female that is not pregnant and agrees to contraceptive use that is consistent with local regulations regarding the methods of contraception to be used during the study
Males agree to use a highly effective method of contraception and will refrain from donating sperm from the first dose of any study intervention
Participant is capable of giving signed informed consent

Exclusion Criteria

Symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the Investigator's best judgment
Peritoneal carcinomatosis
Inflammatory breast cancer at screening
Participant with central nervous system (CNS) involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases
Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
Has a history of prolonged QT syndrome or Torsades de Pointes
Has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy) or any CDK4/6 inhibitor
Has received prior treatment with fulvestrant
Use of systemic estrogens
Participant is currently receiving any of the following substances and cannot be discontinued 14 days prior to start the treatment
Known strong or moderate CYP3A inducers or strong inhibition of CYP3A
Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
Echocardiogram done within the past 12 months with ejection fraction of ≤ 45% or
documented history of congestive heart failure with reduced ejection fraction
Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or oral temperature > 38°C at screening
Interstitial pneumonia or severe impairment of lung function
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note